Why IMU is a multi multi bagger, page-22597

Hi freebooter,

Yes, I would expect that the first patients in the expansion Cholangiocarcinoma trial will start on the highest dose that has ‘cleared’ in the MAST study, so 3x10⁸. Did I read somewhere that they may be cleared to dose escalate depending on what they are seeing in the MAST study?

As I have stated before, they may not take all applicants that ‘front up’ (and I think there will be many after the conference) because they will want the best candidates. Amongst other things there will be some serious blood screening happening prior to admission. The team will specifically be looking for bloods that show high levels of T cell diversity to further lift any anti-tumour T cell response.

I will certainly be watching this trial with great interest.

Hi Fibber,

Yes, I believe the PR was from a very low dose while the CR came from what IMU are calling a mid-dose. This expansion trial will open with a much higher dose and with a lot learned from their ‘sandbox’ study.

I love it ...

better informed = better trial structure = targeted candidates = greater chance of success !

Now let’s see what these higher doses can do for our ‘best candidates’. Could be a knock out.

Hi T-Bull,

Yes, very nice to see both Yuman and Leslie at the Cholangiocarcinoma conference. This is great timing for us, as you mention.

As special invitees, IMU’s session should be well attended. I expect that this trial will be followed by Bile Duct cancer specialists from around the world. Can I even suggest that Big Pharma will also be very interested.

This MAST study may spin-off expansion trials ‘left, right and centre’, hence my eagerness to see the next cut data in the MAST study.

As always, my opinion only.